Ziyu Xun

Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Journal: Chinese medical journal

Published: December 02, 2025

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

Journal: Cell metabolism

Published: August 14, 2025

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Journal: Signal transduction and targeted therapy

Published: July 31, 2025

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: May 27, 2025

Global research landscape and trends of immunotherapy in biliary tract cancers.

Global research landscape and trends of immunotherapy in biliary tract cancers.

Journal: Chinese medical journal

Published: May 08, 2025

Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.

Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.

Journal: Hepatology (Baltimore, Md.)

Published: April 29, 2025

Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.

Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.

Journal: Gut

Published: April 04, 2025

Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: March 03, 2025

FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.

FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.

Journal: Nature communications

Published: February 07, 2025

Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.

Effectiveness and safety of PD-1/PD-L1 inhibitors plus lenvatinib with or without Gemox chemotherapy in advanced intrahepatic cholangiocarcinoma.

Journal: BMC cancer

Published: December 26, 2024

Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications.

Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications.

Journal: International immunopharmacology

Published: November 25, 2024

Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.

Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.

Journal: Journal of advanced research

Published: September 14, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026